🏢 What Kind of Company Is Bright Green Corporation?

Bright Green Corporation is a U.S. company founded in 2019 and headquartered in Grants, New Mexico. It sought to produce and supply plant-based controlled substances listed as Schedule I or II under its U.S. Drug Enforcement Administration registration. Through the domestic production of pharmaceutical ingredients derived from plants, including cannabis extracts, psilocybin, and poppy derivatives, it promoted a “Drugs Made in America” strategy intended to reduce U.S. import dependence. However, it was delisted from NASDAQ in September 2024 and filed for Chapter 11 bankruptcy protection in February 2025.

💰 How Does It Make Money?

The company has generated no commercial revenue to date. Its planned business model was to supply DEA-approved plant-based active pharmaceutical ingredients to pharmaceutical companies and research institutions.

The company’s DEA registration, which approves the manufacture of all plant-based Schedule I and II drugs, has value as a regulatory asset. However, the company has filed for bankruptcy protection without any record of successful commercialization.

📐 Market Capitalization and Company Size

Bright Green is a microcap company currently trading over the counter under the symbol BGXXQ. Its market capitalization is approximately {{MARKET_CAP}}, equal to about {{SAMSUNG_RATIO}} of Samsung Electronics’ market capitalization. It has a small workforce of approximately {{EMPLOYEES}} employees and operates a roughly 1 million-square-foot facility in Grants, New Mexico.

📈 Bright Green Corporation Outlook and Stock Performance

After filing for bankruptcy protection in February 2025, the company announced plans to merge with PharmAGRI and relist as “Drugs Made in America Corp.” Its DEA registration aligns with the growth theme of supplying psychedelic and other plant-based pharmaceutical ingredients in the United States, but successful financing and court approval will determine the outcome. Expanding clinical use of psychedelic therapies and U.S. efforts to reduce dependence on foreign pharmaceutical supply chains could provide a favorable backdrop.

⚔️ Key Strengths and Risks

Bright Green holds the rare regulatory asset of a DEA registration, but its bankruptcy filing and lack of revenue are the central risks for investors.

🔄 Competitors and Related Stocks

Competitors and similar companies include publicly traded developers of psychedelic treatments. Compass Pathways (CMPS) and MindMed (MNMD) are conducting clinical trials involving psilocybin. Cybin (CYBN) and Atai Life Sciences (ATAI) also develop psychedelic therapies.

Related companies that could benefit include Jazz Pharmaceuticals (JAZZ), which has an FDA-approved cannabis-derived medicine, and Tilray Brands (TLRY), an integrated cannabis and pharmaceutical company. Both could benefit from changes in the regulatory environment.

Review the real-time stock prices and key metrics of these related companies in the table below.

✅ Investor Checklist

Bright Green Corporation holds a rare DEA registration, but it is currently an extremely high-risk speculative stock in bankruptcy protection. It is not suitable for ordinary investors.

As an over-the-counter stock in bankruptcy protection, the company’s existing shareholders could lose their entire stakes depending on the restructuring outcome. Investors should exercise extreme caution and avoid treating it as anything other than a speculative position.

In summary, Bright Green Corporation holds potential value through its DEA registration but remains an extremely high-risk stock in bankruptcy protection. Investors should closely monitor the restructuring process and consider exposure only in extremely small amounts.

View Bright Green Corporation’s real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today’s real-time dashboard.